Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions
07:00am, Wednesday, 03'rd Feb 2021
WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
04:05am, Saturday, 30'th Jan 2021
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private i
Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting
11:09am, Thursday, 14'th Jan 2021
Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPOd in Aug
Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
04:01pm, Tuesday, 05'th Jan 2021
WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein
Kymera Therapeutics Announces Key Leadership Appointments
07:00am, Wednesday, 16'th Dec 2020
WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protei
WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protei
Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
08:00am, Monday, 23'rd Nov 2020
WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that s
Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
08:00am, Wednesday, 11'th Nov 2020
WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that s
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
07:00am, Thursday, 05'th Nov 2020
Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi
WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein
U.S. IPO Week Ahead: The IPO Market Braces For A September SNOWstorm In A 12-IPO Week
11:07am, Sunday, 13'th Sep 2020
The post-Labor Day IPO frenzy is here as 12 IPOs plan to raise $6.8 billion in the coming week, led by cloud data unicorn Snowflake.
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
06:48am, Sunday, 23'rd Aug 2020
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. The week's eight SPAC IPOs raised $3.3 billion.
